We are live on ! Find out more
PFM

Privium Fund Management Portfolio holdings

AUM $544M
1-Year Est. Return 72.49%
This Fund
S&P 500
This Quarter Est. Return
-2.39%
1 Year Est. Return
+72.49%
3 Year Est. Return
+451.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$384M
AUM Growth
-$58.3M
Cap. Flow
-$20.7M
Cap. Flow %
-5.39%
Top 10 Hldgs %
77.1%
Holding
69
New
5
Increased
21
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$5.71M
2
ARWR icon
Arrowhead Research
ARWR
+$4.52M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.87M
4
IMVT icon
Immunovant
IMVT
+$1.51M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.47M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$8.11M
2
SMR icon
NuScale Power
SMR
+$6.45M
3
SNOW icon
Snowflake
SNOW
+$4.58M
4
IONQ.WS
IonQ Inc Warrants
IONQ.WS
+$3.9M
5
MRK icon
Merck
MRK
+$2.94M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 29.62%
2 Technology 24.05%
3 Healthcare 23.5%
4 Communication Services 20.98%
5 Energy 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPOT icon
1
Spotify
SPOT
$113B
$80.5M 20.98%
145,000
– –
TSLA icon
2
Tesla
TSLA
$1.38T
$57.4M 14.96%
220,000
– –
SHOP icon
3
Shopify
SHOP
$197B
$39.8M 10.38%
415,000
– –
PLTR icon
4
Palantir
PLTR
$448B
$30.6M 7.98%
360,000
-10,000
-3% -$878K
SE icon
5
Sea Limited
SE
$73.1B
$27.4M 7.15%
210,000
– –
AMZN icon
6
Amazon
AMZN
$2.87T
$27M 7.03%
141,000
– –
RARE icon
7
Ultragenyx Pharmaceutical
RARE
$2.52B
$9.05M 2.36%
249,804
-8,576
-3% -$357K
IONS icon
8
Ionis Pharmaceuticals
IONS
$10.1B
$8.07M 2.1%
267,594
+800
+0.3% +$26.2K
ARWR icon
9
Arrowhead Research
ARWR
$12B
$8.02M 2.09%
629,214
+248,628
+65% +$4.52M
NVDA icon
10
NVIDIA
NVDA
$5.25T
$7.93M 2.07%
73,000
– –
SNOW icon
11
Snowflake
SNOW
$114B
$7.13M 1.86%
48,000
-27,000
-36% -$4.58M
NET icon
12
Cloudflare
NET
$107B
$6.76M 1.76%
60,000
– –
PRQR icon
13
ProQR Therapeutics
PRQR
$323M
$6.63M 1.73%
4,985,633
– –
AXSM icon
14
Axsome Therapeutics
AXSM
$10.4B
$6.15M 1.6%
52,732
-9,500
-15% -$1.08M
QURE icon
15
uniQure
QURE
$3.38B
$6.14M 1.6%
579,139
-163,023
-22% -$2.29M
SWTX
16
DELISTED
SpringWorks Therapeutics
SWTX
$5.47M 1.43%
+123,980
New +$5.71M
ARQT icon
17
Arcutis Biotherapeutics
ARQT
$2.99B
$5.09M 1.33%
325,709
– –
ZLAB icon
18
Zai Lab
ZLAB
$2.93B
$4.78M 1.25%
132,189
-52,873
-29% -$1.63M
VRTX icon
19
Vertex Pharmaceuticals
VRTX
$137B
$4.02M 1.05%
+8,300
New +$3.87M
MRK icon
20
Merck
MRK
$366B
$3.69M 0.96%
41,093
-31,518
-43% -$2.94M
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$424M
$2.89M 0.75%
432,760
+35,110
+9% +$347K
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$5.02B
$2.46M 0.64%
148,400
– –
MRNA icon
23
Moderna
MRNA
$55.1B
$2.14M 0.56%
75,576
-6,900
-8% -$245K
CRSP icon
24
CRISPR Therapeutics
CRSP
$5.58B
$2.05M 0.53%
60,097
+25,100
+72% +$1.06M
ABEV icon
25
Ambev
ABEV
$44.1B
$1.87M 0.49%
804,206
+151,849
+23% +$304K
1
2 3

Similar funds

RWMH
Riverpoint Wealth Management Holdings Chicago, Illinois $544M AUM 20.39% 1-Year Est. Return
BPIA
Broad Peak Investment Advisers Singapore $544M AUM 132.56% 1-Year Est. Return
AFA
Abacus FCF Advisors Orlando, Florida $544M AUM 70.51% 1-Year Est. Return
TC
TownSquare Capital Provo, Utah $544M AUM 40.38% 1-Year Est. Return
FIM
FWL Investment Management Dallas, Texas $545M AUM 64.06% 1-Year Est. Return
DKAM
Drummond Knight Asset Management Crows Nest, NSW, Australia $545M AUM 73.62% 1-Year Est. Return
CCM
Coerente Capital Management Toronto, Ontario, Canada $543M AUM 7.53% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Privium Fund Management's Q1 2025 Portfolio in Review

As of Q1 2025, Privium Fund Management held 69 positions worth $384M, down 13% from $442M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Privium Fund Management withdrew a net $20.7M in Q1 2025, closing 13 positions and reducing 13 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $8.11M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 30% of assets, down from 33% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Privium Fund Management opened a new position in SpringWorks Therapeutics worth $5.47M.

  • Privium Fund Management's largest Q1 2025 buy was SpringWorks Therapeutics: 123,980 shares worth $5.47M.
  • Privium Fund Management added most to Arrowhead Research in Q1 2025, an estimated $4.52M increase.
  • Privium Fund Management's biggest Q1 2025 reduction was Snowflake, cutting an estimated $4.58M.
  • Privium Fund Management fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $8.11M.
  • Privium Fund Management's ten largest holdings make up 77% of its $384M portfolio in Q1 2025.
  • Privium Fund Management opened 5 new positions and closed 13 in Q1 2025.
  • Privium Fund Management's portfolio value fell 13% quarter-over-quarter to $384M.

Based on Privium Fund Management's 13F filing for Q1 2025, filed 9 May 2025.